4 completed, 1 active not recruiting, 1 terminated, 1 unknown. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 4, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Serotonin Syndrome: new trials by email Literature Review of Serotonin Syndrome trials Research Report on Serotonin Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Paltusotine, Placebo - Carcinoid Syndrome, Carcinoid | Phase 3 | Active not recruiting | Crinetics Pharmaceuticals Inc. | 141 | 2025-11-19 | 2026-10-15 |
| Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial Cyproheptadine Hydrochloride 4 MG - Viral Pneumonia, Serotonin Syndrome | Phase 3 | Unknown | Ciusss de L'Est de l'Île de Montréal | 200 | 2021-04-10 | 2021-04-02 |
| Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Telotristat Ethyl, Lanreotide - Small Intestinal NET, Carcinoid Heart Disease | Phase 3 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2020-04-01 | 2020-02-05 | |
| Telotristat Etiprate for Carcinoid Syndrome Therapy Telotristat etiprate, Placebo - Carcinoid Syndrome | Phase 3 | Completed | Lexicon Pharmaceuticals | 76 | 2014-03-11 | 2018-02-26 |
| Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Telotristat etiprate - Carcinoid Syndrome | Phase 3 | Completed | Lexicon Pharmaceuticals | 124 | 2014-01-14 | 2019-09-17 |
| TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Telotristat etiprate, Placebo-matching telotristat etiprate - Carcinoid Syndrome | Phase 3 | Completed | Lexicon Pharmaceuticals | 135 | 2013-01-08 | 2018-02-27 |
| An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Lanreotide, Placebo - Carcinoid Syndrome | Phase 3 | Completed | Ipsen | 115 | 2009-05-01 | 2022-10-14 |
| Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue) - Malignant Carcinoid Syndrome | Phase 3 | Terminated | Ipsen | 4 | 2004-07-01 | 2020-04-30 |
Carcinoid Tumor (2) · Neuroendocrine Tumors (2) · COVID-19 (1) · Carcinoid Heart Disease (1) · Carcinoid Tumors, Intestinal (1) · Diarrhea (1) · Flushing (1) · Malignant Carcinoid Syndrome (1) · Pneumonia, Viral (1)
Chemically-Induced Disorders (8) · Drug-Related Side Effects and Adverse Reactions (8) · Adenocarcinoma (4) · Carcinoma (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Carcinoid Tumor (2) · Neuroendocrine Tumors (2) · Cardiovascular Diseases (1) · Coronaviridae Infections (1) · Coronavirus Infections (1)
telotristat (3) · lanreotide (2) · Cyproheptadine (1) · Receptor-Like Protein Tyrosine Phosphatases, Class 2 (1) · Standard of Care (1) · telotristat ethyl (1)
Lexicon Pharmaceuticals (3) · Ipsen (2) · Ciusss de L'Est de l'Île de Montréal (1) · Crinetics Pharmaceuticals Inc. (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)
United States (6) · Belgium (4) · France (4) · Germany (4) · Spain (4) · United Kingdom (4) · Australia (3) · Canada (3) · Israel (3) · Italy (3) · Netherlands (3) · Sweden (3) · Brazil (2) · Poland (2) · Argentina (1)
Pablo Lapuerta, MD (3) · Angela Lamarca (1) · Juan Valle (1)
PMID 32146619, PMID 34598813, PMID 27214300, PMID 29330194, PMID 29724499, PMID 30477789, PMID 31655936, PMID 31754316, PMID 32157590, PMID 33940581
2004 (1)